Clay Siegall is an ambitious scientist who has been eager to learn new concepts every day of his life since childhood. His father died when he was 24 after struggling with cancer. This raised Siegall’s concern, and he began wondering if anything could be done to curb cancer or at least alleviate the suffering experienced by cancer patients. This could be the main reason Siegall committed his life to helping cancer patients. He believes in collaboration with scientists and medical professionals to bring new ideas and approaches that can improve cancer therapy. As a result, Clay has played a significant role in the industry for the last 30 years, and the progress of treating cancer inspires him to move on.
Clay received a Bachelor’s Degree in Zoology from the University of Maryland and later a Ph.D. in Genetics that he pursued at the University of George Washington. After graduating, he got a job with Bristol–Meyer Squib in their Pharmaceutical Research Institute. He has also worked for the National Cancer Institute and the National Institutes of Health. Due to his education background, he held a senior position at Alder Pharmaceutical, Ultragenyx Pharmaceutical, and Washington Roundtable as a member of the Board of Directors. Over the years that Clay Siegall worked for those institutions, he gathered sufficient knowledge and experience in leadership, research, drug development, and innovative cancer therapies that propelled him towards attaining his goal of enhancing cancer treatment procedures.
Clay Siegall founded Seattle Genetics in 1998 to provide a suitable environment for cancer research and drug development. Seattle Genetics is a biotechnology firm focusing on the development of anti-body therapies for cancer treatment. Driven by the passion for helping patients, he has engaged in rigorous research, scientific advances and development of cancer drugs through his firm, Seattle Genetics. Under Clay’s effective leadership, Seattle has developed Antibody-drug conjugates (ADC’s). ADCETRIS was the first cancer treatment product to receive FDA approval, and it is now available in more than 65 countries globally. Seattle has collaborated with Takeda Pharmaceutical to develop and market the effective drug. Besides the achievement at Seattle Genetics, Clay has published more than 70 journals, and he holds 15 patents.